Transferrin conjugated poly (γ-glutamic acid-maleimide-co-l-lactide)-1,2-dipalmitoylsn-glycero-3-phosphoethanolamine copolymer nanoparticles for targeting drug delivery

Colloids and Surfaces B: Biointerfaces

Volumn 123, Issue , 2014, Pages 787-796

  Zhao, Caiyan ^a   Liu, Xiaoguang ^a,b   Liu, Junxing ^b   Yang, Zhiwei ^b   Rong, Xianghui ^b   Li, Mingjun ^b   Liang, Xingjie ^a   Wu, Yan ^a  

^a NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

^b JIAMUSI UNIVERSITY   (China)

Author keywords

1,2 Dipalmitoylsn glycero 3 phosphoethanolamine; Amphiphilic copolymer; Paclitaxel; Poly glutamic acid; Targeting delivery system; Transferrin

Indexed keywords

AMINO ACIDS; BIOCOMPATIBILITY; CELLS; CHEMOTHERAPY; COPOLYMERS; CYTOLOGY; DISEASES; DRUG DELIVERY; ENCAPSULATION; PARTICLE SIZE; TUMORS;

1,2-DIPALMITOYLSN-GLYCERO-3-PHOSPHOETHANOLAMINE; AMPHIPHILIC CO-POLYMERS; GLUTAMIC ACID; PACLITAXEL; TARGETING DELIVERIES; TRANSFERRIN;

NANOPARTICLES;

COPOLYMER; NANOPARTICLE; PACLITAXEL; POLY(GAMMA GLUTAMIC ACID MALEIMIDE CO LEVO LACTIDE) 1,2 DIPALMITOYLSN GLYCERO 3 PHOSPHOETHANOLAMINE COPOLYMER; TRANSFERRIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCOMPATIBILITY; CANCER INHIBITION; CELL TRANSPORT; CONFOCAL LASER MICROSCOPY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG TARGETING; FLOW CYTOMETRY; HELA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; NANOENCAPSULATION; NASOPHARYNX CARCINOMA; PARTICLE SIZE; PH MEASUREMENT; PROTEIN EXPRESSION; PROTEIN MODIFICATION; UTERINE CERVIX CARCINOMA;

EID: 84915792850     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2014.10.024     Document Type: Article

References (41)

1. Wong H.L., Bendayan R., Rauth A.M., Li Y., Wu X.Y. Adv. Drug Deliv. Rev. 2007, 59:491-504.
2. Song H., He R., Wang K., Ruan J., Bao C., Li N., Ji J., Cui D. Biomaterials 2010, 31:2302-2312.
3. Tobío M., Sánchez A., Vila A., Soriano I., Evora C., Vila-Jato J.L., Alonso M.J. Colloids Surf. B: Biointerfaces 2000, 18:315-323.
4. Maeda H., Bharate G.Y., Daruwalla J. Eur. J. Pharm. Biopharm. 2009, 71:409-419.
5. Farokhzad O.C., Cheng J., Teply B.A., Sherifi I., Jon S., Kantoff P.W., Richie J.P., Langer R. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:6315-6320.
6. Byrne J.D., Betancourt T., Brannon-Peppas L. Adv. Drug Deliv. Rev. 2008, 60:1615-1626.
7. Choi C.H.J., Alabi C.A., Webster P., Davis M.E. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:1235-1240.
8. Cheng Y., Zak O., Aisen P., Harrison S.C., Walz T. Cell 2004, 116:565-576.
9. Bellocq N.C., Pun S.H., Jensen G.S., Davis M.E. Bioconjug. Chem. 2003, 14:1122-1132.
10. Qian Z.M., Li H., Sun H., Ho K. Pharmacol. Rev. 2002, 54:561-587.
11. Liu X., Su S., Wei F., Rong X., Yang Z., Liu J., Li M., Wu Y. J. Colloid Interface Sci. 2014, 413:54-64.
12. Shih I.-L., Van Y.-T. Bioresour. Technol. 2001, 79:207-225.
13. Liang H.-F., Chen C.-T., Chen S.-C., Kulkarni A.R., Chiu Y.-L., Chen M.-C., Sung H.-W. Biomaterials 2006, 27:2051-2059.
14. Verrecchia T., Spenlehauer G., Bazile D.V., Murry-Brelier A., Archimbaud Y., Veillard M. J. Control. Release 1995, 36:49-61.
15. Yasugi K., Nagasaki Y., Kato M., Kataoka K. J. Control. Release 1999, 62:89-100.
16. Liang H.-F., Yang T.-F., Huang C.-T., Chen M.-C., Sung H.-W. J. Control. Release 2005, 105:213-225.
17. Soenen S.J.H., Illyes E., Vercauteren D., Braeckmans K., Majer Z., De Smedt S.C., De Cuyper M. Biomaterials 2009, 30:6803-6813.
18. Wang T., Zhang C., Liang X.-J., Liang W., Wu Y. J. Pharm. Sci. 2011, 100:1067-1079.
19. Zhang L., Guo R., Yang M., Jiang X., Liu B. Adv. Mater. 2007, 19:2988-2992.
20. Rowinsky E.K., Donehower R.C. N. Engl. J. Med. 1995, 332:1004-1014.
21. Singla A.K., Garg A., Aggarwal D. Int. J. Pharm. 2002, 235:179-192.
22. Cai W., Zhang X., Wu Y., Chen X. J. Nucl. Med. 2006, 47:1172-1180.
23. Zhan C., Gu B., Xie C., Li J., Liu Y., Lu W. J. Control. Release 2010, 143:136-142.
24. Hojo H., Onuma Y., Akimoto Y., Nakahara Y., Nakahara Y. Tetrahedron Lett. 2007, 48:25-28.
25. de Bruin B., Kuhnast B., Hinnen F., Yaouancq L., Amessou M., Johannes L., Samson A., Boisgard R., Tavitian B., Dollé F. Bioconjugate Chem. 2005, 16:406-420.
26. Huwyler J., Wu D., Pardridge W.M. Proc. Natl. Acad. Sci. 1996, 93:14164-14169.
27. He H., Li Y., Jia X.-R., Du J., Ying X., Lu W.-L., Lou J.-N., Wei Y. Biomaterials 2011, 32:478-487.
28. Zhang Z., Feng S.-S. Biomaterials 2006, 27:4025-4033.
29. Wang T., Wu Y., Zeng A.J. J. Appl. Polym. Sci. 2010, 117:604-613.
30. Zhang Y.-f., Wang J.-c., Bian D.-y., Zhang X., Zhang Q. Eur. J. Pharm. Biopharm. 2010, 74:467-473.
31. Nallamothu R., Wood G., Pattillo C., Scott R., Kiani M., Moore B., Thoma L. AAPS PharmSciTech 2006, 7:E7-E16.
32. Jain R.A. Biomaterials 2000, 21:2475-2490.
33. Mu L., Feng S.-S. Pharm. Res. 2003, 20:1864-1872.
34. Tannock I.F., Rotin D. Cancer Res. 1989, 49:4373-4384.
35. Wojtkowiak J.W., Verduzco D., Schramm K.J., Gillies R.J. Mol. Pharm. 2011, 8:2032-2038.
36. Connor J., Yatvin M.B., Huang L. Proc. Natl. Acad. Sci. U. S. A. 1984, 81:1715-1718.
37. Gerasimov O.V., Boomer J.A., Qualls M.M., Thompson D.H. Adv. Drug Deliv. Rev. 1999, 38:317-338.
38. Pawelczyk E., Arbab A.S., Pandit S., Hu E., Frank J.A. NMR Biomed. 2006, 19:581-592.
39. Wang J., Tian S., Petros R.A., Napier M.E., DeSimone J.M. J. Am. Chem. Soc. 2010, 132:11306-11313.
40. Gan C.W., Feng S.-S. Biomaterials 2010, 31:7748-7757.
41. Maeda H., Greish K., Fang J. The EPR effect and polymeric drugs: a paradigm shift for cancer chemotherapy in the 21st century. Polymer Therapeutics II 2006, 103-121. Springer, Berlin/Heidelberg. R. Satchi-Fainaro, R. Duncan (Eds.).